Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
13 mars 2019 09h00 HE
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, March 13, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the acceptance of an abstract for a late-breaker oral presentation at The International...
Conatus Pharmaceuticals Reports 2018 Financial Results and Program Updates
08 mars 2019 16h05 HE
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, March 08, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2018, and provided...
Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results
01 mars 2019 07h30 HE
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, March 01, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31,...
Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis
12 févr. 2019 07h30 HE
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the...
Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials
28 janv. 2019 07h30 HE
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced publications expanding on previously reported results from three of the company’s completed...
Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
05 déc. 2018 07h30 HE
|
Conatus Pharmaceuticals Inc.
- Clinically Meaningful Improvements in Portal Hypertension in High Risk Compensated Cirrhosis Patients - - Conference Call and Webcast Presentation at 8:30 a.m. ET Today - SAN DIEGO, Dec. ...
Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting
08 nov. 2018 07h30 HE
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the schedule of upcoming oral presentations and posters addressing clinical and preclinical...
Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates
01 nov. 2018 16h05 HE
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results
25 oct. 2018 07h30 HE
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the third quarter ended September 30, 2018, after...
Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting
02 oct. 2018 16h05 HE
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that two abstracts – one addressing clinical results with the company’s pan-caspase...